Japanese Journal of Thrombosis and Hemostasis
Online ISSN : 1880-8808
Print ISSN : 0915-7441
ISSN-L : 0915-7441
Volume 33, Issue 1
Displaying 1-17 of 17 articles from this issue
New Year’s Greeting
Editorial
Reviews: Non-factor replacement therapies for hemophilia
Review
Topics: A new series “COVID-19 Infecion”
Original article
  • Teruhisa FUJII, Keiji NOGAMI, Midori SHIMA, Hiromi TERAYAMA, Fumihiko ...
    Article type: Original article
    2022 Volume 33 Issue 1 Pages 60-68
    Published: 2022
    Released on J-STAGE: February 25, 2022
    JOURNAL FREE ACCESS FULL-TEXT HTML

    Albutrepenonacog alfa, a fusion protein that links recombinant coagulation factor IX (rFIX) with recombinant human albumin, was developed to prolong its half-life and reduce the number of administration, and was approved in Japan in 2016. This is a 4-year interim report of a post-marketing surveillance study in hemophilia B patients who received albutrepenonacog alfa. Of the patients included in the safety analysis set (n = 68), 64 patients used albutrepenonacog alfa for prophylaxis, 27 patients for on-demand therapy, five patients for perioperative bleeding control, and 13 patients for other reasons during observation period (including duplicates), and hemostasis was achieved with a single administration in six of eight cases in five patients for perioperative bleeding control. No safety concerns were observed during the observation period. In the prophylaxis effectiveness analysis set who continued prophylaxis for more than 6 months (n = 41), the median number of bleeding episodes was 0, and 24 patients (58.5%) received albutrepenonacog alfa at dosage intervals of 7 days at 6 months after the start of prophylaxis.

Technical Lecture
Small talks on my research career
Overseas Laboratory Now!!
2021 Hot Topics
Journal Club
feedback
Top